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| INTRODUC TI ON
Previous studies have evaluated the clinical validity of donor-derived cell-free DNA fraction (dd-cfDNA[%]) as a noninvasive biomarker for comprehensive monitoring of allograft injury, [1] [2] [3] [4] [5] [6] including in kidney transplantation (KTx). Since organ transplants are also genome transplants, this enables the discrimination of donor-from hostderived cfDNA and noninvasive monitoring for allograft injury. 2 This new approach could be useful to personalize immunosuppression and thereby improve outcomes.
There are about 19 000 KTx per year with over 200 000 living kidney allograft recipients in the United States. 7 The 10-year US kidney allograft survival rate is on average only 55% (47% for deceased, 63% for living donor transplants). 8 This suboptimal graft survival rate illustrates the limitations of current methods used to monitor and treat KTx patients. About 100 000 patients are on waiting lists for KTx and 5000 to 10 000 kidney patients die prematurely each year. 9 The median waiting time for a kidney is 3.6 years. The shortage of donor organs makes it especially important to reduce premature graft loss.
Long-term patient outcome after KTx is limited by multiple factors, namely irreversible chronic allograft dysfunction, acute or chronic rejection, and adverse effects of standard immunosuppression such as nephrotoxicity, cardiovascular disease, opportunistic infection, and malignancies.
Current diagnostic measures are unreliable for the early detection of kidney graft injury including acute and chronic rejection as well as subclinical rejection. Changes in plasma creatinine are most commonly used to decide whether a renal biopsy should be done to detect rejection. However, plasma creatinine is a measure of glomerular function rather than kidney tissue damage. An increase of plasma creatinine may also be due to exsiccation, the use of angiotensin converting enzyme (ACE) inhibitors, or immunosuppressive drug (ISD) toxicity. By the time a rejection-related increase in plasma creatinine is evident, a significant degree of tissue damage has already occurred within the kidney. 10 Therefore, interventions based on plasma creatinine may be too late or even inappropriate. ISD monitoring mainly indicates potential toxicity, but is a poor biomarker of graft damage. 11 A further limitation of the current standard of care is that rejection episodes can be confirmed only by biopsies. However, serial biopsies to assess graft integrity (eg, to adjust and individualize ISD treatment) are clinically impractical, costprohibitive, and a major burden for patients since biopsies have uncommon, but potentially serious complications. In addition, the reliability of biopsies is also limited, being prone to sampling and interpretation errors, and also have turnaround times that limit their usefulness for making rapid decisions. 12 Against this background, rapid dd-cfDNA determination has great potential as a noninvasive biomarker for early detection of acute or chronic rejection after KTx. Further important areas of application include the detection of asymptomatic graft injury leading to irreversible damage, the detection of under-immunosuppression associated with the risk of de novo donor-specific antibody (DSA) formation and subsequent graft loss, 13 including the assessment of minimal necessary exposure to guide tapering and prevent immune activation.
At least 47 published studies in solid organ transplantation have investigated dd-cfDNA(%) using shotgun or targeted nextgeneration sequencing, or droplet digital PCR (ddPCR). 5 For noninvasive routine monitoring, ddPCR seems to be a very practical approach with a clinically acceptable turnaround time (same day).
dd-cfDNA(%) has recently been reported to be a sensitive, noninvasive biomarker of kidney transplant rejection superior to serum creatinine. 4 Methods determining dd-cfDNA(%), however, have the potential disadvantage of being affected by changes in the circulating recipient cfDNA. 14 
| MATERIAL S AND ME THODS

| Study design
| Blood collection and cfDNA extraction
| Measurement of dd-cfDNA fraction(%)
The fractional abundance of the circulating donor-derived DNA was determined by the dd-cfDNA-ddPCR method version-1 as previously described 15, 16 and detailed data on the analytical validity are given in the Supporting Information. Different from the original method, urine DNA was used for the determination of the informative SNP set for 158 of the 189 patients, since it is enriched with graft DNA.
| dd-cfDNA(cp/mL) quantification
Absolute quantification of haploid GcDNA genomic copies per mL plasma(cp/mL) is calculated by multiplying the total concentration of cfDNA(cp/mL) in a sample by the dd-cfDNA fraction(%). The concentration of the total cfDNA is determined by a droplet digital PCR and is corrected for extraction efficiency and the reduced PCR efficiency resulting from the fragmentation of the cfDNA (see Supporting Information for further details).
| Criteria for inclusion of samples and subgroup assignments
A total of 189 patients (N) had samples (n) drawn at time points that met preestablished inclusion criteria for use in the statistical analyses.
The same patients could have samples assigned to various subcategories, depending on time after transplantation and their clinical condition around the sampling time (Supporting Information, Figure S1 ).
Criteria for inclusion and numbers in sample subcategories defined as "Non-rejecting Phase," "Stable Phase," "Negative Biopsy," "Borderline TCMR," "BPR," and "IF/TA" were:
• 
| Histopathologic diagnosis
| Statistical analysis
All statistical analyses were performed using R 3.5.1 (2018-07-02).
Continuous data were presented with median and interquartile range Table S1 and Figure S6 ).
ROC analyses were performed to assess how well dd-cfDNA fraction(%) and dd-cfDNA(cp/mL) discriminated between Stable Phase and BPR subgroups. ROC curves and AUCs were reported with 95% bootstrap CI. 21, 22 Optimal thresholds were calculated using simultaneous maximization of sensitivity and specificity. 23, 24 Sensitivity and specificity were reported with 95% bootstrap CI. Diagnostic odds ratios at optimal thresholds were reported with 95% CI.
A sensitivity analysis using one randomly chosen value per patient to evaluate the effect of repeated measures on the ROC analysis was conducted. Reference change values were calculated as described under Supporting Information.
| RE SULTS
| Time dependence of dd-cfDNA
The time dependence of dd-cfDNA after KTx in the absence of clinically suspected rejection showed the pattern typically seen after solid organ transplantation. All 1104 samples from the "Non- were still numerically higher (98 vs. 68 cp/mL, P = .5) in recipients of grafts from deceased vs living donors, respectively ( Table 2 ). Table S1 ). Seventy-two percent of BPR episodes occurred between 
| Diagnostic performance of dd-cfDNA concentration vs fraction
| Detection of inadequate immunosuppression
The very high negative predictive values for both dd-cfDNA results suggest that these tests can allow avoidance of unnecessary biopsies triggered by elevated or increasing plasma creatinine. This Figure 6 . A similar association (data not shown) was found for tacrolimus concentrations and dd-cfDNA(%). graft failure with return to dialysis causes an average annual expense of 75 836 USD, a multiple of annual costs for a patient with a functioning graft (19 364 USD).
| D ISCUSS I ON
There is emerging evidence for the clinical validity of dd-cfDNA determination for early detection of rejection episodes at an actionable stage. 4, 5, 25, 26 Elevation of dd-cfDNA is not rejection specific, but reveals the degree of graft cell injury, complements histologic findings, and most importantly can help to avoid unnecessary biopsies, based on the high negative predictive value shown herein. As In our study, six of seven negative biopsies triggered by elevated plasma creatinine could have been avoided as dd-cfDNA fraction and concentration were below the respective thresholds. This is particularly important in those patients with a high biopsy risk.
The association found between increased dd-cfDNA values and low tacrolimus concentrations post KTx ( Figure 6 ) suggests that dd-cfDNA can be useful to detect subclinical (ie, clinically unsuspected) graft damage as a result of immune activation triggered by underimmunosuppression. This is consistent with observations in liver transplantation. 28 Persistent under-immunosuppression can cause de novo DSA formation, which increases the risk of subsequent graft loss. 13, [29] [30] [31] Early diagnosis and treatment of subclinical AMR may improve outcomes after KTx. 32, 33 However, the detection of IgG DSA has failed to reliably predict ongoing AMR. 34 AMR is associated with 20% to 30% allograft loss. 35 The results shown in Figure 6 are also consistent with the hypothesis that the dd-cfDNA eleva- So far, studies directly comparing different dd-cfDNA determination methods are lacking. It is encouraging, however, that the median values of clinically stable patients were very similar in different studies using different methods for dd-cfDNA determination. 4, [36] [37] [38] In our cohort, the median was 0.29% (IQR: 0.17%-0.56%). Bromberg 36 Limitations of this study include the lack of protocol biopsies and the fact that the vast majority of patients were of Caucasian origin.
The data from our study support the role of dd-cfDNA as a pivotal addition to the methods currently used to achieve personalized immunosuppression in KTx, such as immunological monitoring, therapeutic drug monitoring, microbial screening, and biopsy. Based on all this information, in agreement with other reports, 5, 37 we are confident that dd-cfDNA can be recommended for clinical translation as a valid tool to aid personalized patient care for the benefit of transplanted patients and healthcare payers. To achieve this, methods providing a fast turnaround time, such as the ddPCR used herein, will allow frequent monitoring and provide actionable results (eg, to aid in decision-making for biopsy).
In conclusion, the absolute quantification of dd-cfDNA(cp/ mL) was superior to dd-cfDNA fraction (%) as a biomarker of BPR. This is presumably because dd-cfDNA(cp/mL), unlike dd-cfDNA(%), is not affected by changes in recipient DNA present in the circulation. We, however, concur with Whitlam et al 14 
DATA AVA I L A B I L I T Y S TAT E M E N T
The data that support the findings of this study are available from the corresponding author upon reasonable request. 
S U PP O RTI N G I N FO R M ATI O N
Additional supporting information may be found online in the Supporting Information section at the end of the article. 
